ideasIdea
Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
India has shown CAR-T can be made for a tenth of the US price. Public production in large middle-income countries could make it available to millions who are currently excluded.
NexCAR19 (ImmunoACT, Tata Memorial and IIT Bombay) was approved in India in 2023 at around $40,000; Brazil's Fiocruz and Butantan and China's academic centres are building comparable capacity. The proposal is a coordinated public-sector programme in three to five large middle-income countries with shared vector supply, shared training, a common product dossier adapted for national regulators, and outcome registries, aimed at treating relapsed B-cell malignancies at under $50,000 per dose within public health systems.
Hypothesis
Public manufacturing programmes treat at least 5,000 patients a year across participating countries within five years at under $50,000 per dose, with complete response rates in relapsed B-ALL and lymphoma comparable to published academic series.
Rationale
Labour, facility and vector costs are far lower in these settings and the demand is enormous; the Indian precedent shows regulatory approval and manufacturing are achievable, and cross-country sharing of vector and know-how spreads fixed costs.
What would test it
Fund two additional national programmes to reach approval using shared vector and process, and report cost, throughput and outcomes at three years against the Indian precedent.
Maturity
early clinical
Who has to act
policy
Cost to try
Large (over $50M)
Years to first evidence
5
Bottlenecks it attacks
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.